WO2020249769A1 - Procédés et compositions pour le traitement de maladies oculaires associées à la maintenance d'adn mitochondrial - Google Patents

Procédés et compositions pour le traitement de maladies oculaires associées à la maintenance d'adn mitochondrial Download PDF

Info

Publication number
WO2020249769A1
WO2020249769A1 PCT/EP2020/066364 EP2020066364W WO2020249769A1 WO 2020249769 A1 WO2020249769 A1 WO 2020249769A1 EP 2020066364 W EP2020066364 W EP 2020066364W WO 2020249769 A1 WO2020249769 A1 WO 2020249769A1
Authority
WO
WIPO (PCT)
Prior art keywords
ssbp1
mtdna
protein
gene
subject
Prior art date
Application number
PCT/EP2020/066364
Other languages
English (en)
Inventor
Cécile DELETTRE
Camille PIRO-MEGY
Emmanuelle SARZI
Maria SOLA
Johannes N SPELBRINK
Marie Pequignot
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Université De Montpellier
Consejo Superior De Investigaciones Cientificas (Csic)
Radboud University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Université De Montpellier, Consejo Superior De Investigaciones Cientificas (Csic), Radboud University filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of WO2020249769A1 publication Critical patent/WO2020249769A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology

Definitions

  • the invention is in the field of ophthalmology. More particularly, the invention relates to methods and compositions for treating ocular diseases related to mitochondrial DNA maintenance.
  • Mitochondrial diseases are clinically heterogeneous and can be caused by mutations in either nuclear or mitochondrial DNA (mtDNA) (1). Mutations in genes known to be essential for mtDNA maintenance are recognized to cause mitochondrial DNA depletion syndromes (MDS) and mtDNA multiple deletion syndromes (2). Such genes encode components of the mtDNA replication machinery (POLG, POLG2, TWNK, TFAM, RNASEH1, MGME1 and DNA2), dNTP supply for mtDNA synthesis (TK2, DGUOK, SUCLG1, SUCLA2, ABAT, RRM2B, TYMP, SLC25A4, AGK and MPV17) and mitochondrial dynamics (OPA1, MFN2).
  • Ocular involvement is a well-known clinical feature of mitochondrial disease that may occur as retinal, macular, optic nerve dysfunction, or progressive external ophthalmoplegia (PEO) and ptosis involving the extraocular muscles.
  • PEO progressive external ophthalmoplegia
  • MDS ocular features are rarely isolated and may be associated with neurological and/or multi- systemic presentation including muscle, liver and kidney.
  • ADOA Autosomal dominant optic atrophy
  • the invention relates to a method for predicting the risk of having or developing ocular disease related to mitochondrial DNA (mtDNA) maintenance in a subject, comprising the steps of: i) identifying at least one mutation in the SSBP1 gene and/or protein; ii) concluding that the subject is at risk of having or developing ocular disease related to mtDNA maintenance when at least one mutation is identified.
  • mtDNA mitochondrial DNA
  • SSBP1 mitochondrial single-stranded DNA- binding protein
  • inventors report heterozygous mutations in mitochondrial single-stranded DNA- binding protein SSBP1 in multiple unrelated families with non-syndromic dominant optic atrophy, associated in half of the cases by a striking occurrence of a foveopathy.
  • SSBP1 is a key protein for the mtDNA replication machinery.
  • Inventors have identified two mutations in SSBP1 in families with dominant optic atrophy and shown that SSBP1 mutation affects mtDNA replication.
  • Patient fibroblasts displayed unstable formation of SSBP1 dimer/tetramer affecting mtDNA replication leading to a decrease of mtDNA copy-number. They provide evidences that SSBP1 deficiency in human results in a novel mtDNA syndrome resulting in an isolated visual defect.
  • the term "predicting" means that the subject to be analyzed by the method of the invention is allocated either into the group of subjects who will have or develop ocular disease related to mtDNA maintenance, or into a group of subjects who will not have or develop ocular disease related to mtDNA maintenance.
  • Having or developing ocular disease related to mtDNA maintenance referred to in accordance with the invention particularly, means that the subject will have higher risk to have or develop ocular disease related to mtDNA maintenance.
  • said risk is elevated as compared to the average risk in a cohort of subjects suffering from ocular disease related to mtDNA maintenance.
  • the risk of having the ocular disease related to mtDNA maintenance in a subject susceptible to suffer from ocular disease related to mtDNA maintenance shall be predicted.
  • the term "predicting the risk”, as used herein, refers to assessing the probability according to which the patient as referred to herein will have or develop ocular disease related to mtDNA maintenance.
  • the p-values are, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001.
  • the probability envisaged by the invention allows that the prediction of an increased risk will be correct for at least 60%, at least 70%, at least 80%), or at least 90% of the subjects of a given cohort or population.
  • the term "ocular disease” refers to diseases in the eye.
  • the ocular disease is selected from the group consisting of but not limited to: cataract, age-related macular degeneration (AMD), glaucoma, retinal diseases etc.
  • AMD age-related macular degeneration
  • the ocular disease is related to mtDNA maintenance.
  • ocular involvement is a well- known clinical feature of mitochondrial disease that may occur as retinal, macular, optic nerve dysfunction, or progressive external ophthalmoplegia (PEO) and ptosis involving the extraocular muscles.
  • PEO progressive external ophthalmoplegia
  • mtDNA refers to mitochondrial DNA.
  • mtDNA mitochondrial DNA
  • MDS mitochondrial DNA depletion syndromes
  • SSBP1 mitochondrial DNA
  • SSBP1 mitochondrial DNA
  • protein level affects the fidelity of the mtDNA replication, but does not promote mtDNA recombination.
  • inventors have shown that ocular diseases caused by pathogenic variants in the nuclear genes involved in mtDNA maintenance resulting in impaired mtDNA synthesis leading to quantitative (mtDNA depletion) and qualitative (multiple mtDNA deletions) defects in mtDNA.
  • the method according to the invention wherein the ocular disease related to mtDNA maintenance is selected from the group consisting of but not limited to: optic neuropathy, Autosomal dominant optic atrophy (ADOA), Foveopathy, Leber's hereditary optic neuropathy (LHON), glaucoma, retinal macular dystrophy, optic nerve dysfunction, or progressive external ophthalmoplegia (PEO), or ptosis involving the extraocular muscles.
  • ADOA Autosomal dominant optic atrophy
  • LHON Leber's hereditary optic neuropathy
  • PEO progressive external ophthalmoplegia
  • the ocular disease related to mitochondrial DNA (mtDNA) maintenance is optic neuropathy.
  • the optic nerve contains axons of nerve cells that emerge from the retina, leave the eye at the optic disc, and go to the visual cortex where input from the eye is processed into vision.
  • the term“optic neuropathy” refers to damage to the optic nerve due to any cause. Damage and death of these nerve cells, leads to characteristic features of optic neuropathy.
  • the optic neuropathy can result from various reasons, such as, Ischemic optic neuropathy, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Traumatic optic neuropathy, mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, hereditary optic neuropathies.
  • the optic neuropathy condition may be selected from such conditions as, but not limited to: traumatic neuropathy (that may result from any type of trauma to the optic nerve); ischemic neuropathy (such as, for example, Nonarteritic Anterir Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION), Posterior ischemic optic neuropathy); Radiation optic neuropathy (RON)), Glaucoma, Optic neuritis, Compressive optic neuropathy, Infiltrative optic neuropathy, Mitochondrial optic neuropathy, Nutritional optic neuropathies, toxic optic neuropathies, Hereditary optic neuropathy and the like; or combinations thereof.
  • traumatic neuropathy that may result from any type of trauma to the optic nerve
  • ischemic neuropathy such as, for example, Nonarteritic Anterir Ischemic Optic neuropathy (NAION), Anterior ischemic optic neuropathy (AION), Posterior ischemic optic neuropathy
  • Radiation optic neuropathy (RON)) Glaucoma
  • the ocular disease related to mitochondrial DNA (mtDNA) maintenance is Autosomal dominant optic atrophy (ADOA).
  • ADOA is characterized by progressive visual loss, central scotoma, dyschromatopsia and optic atrophy due to degeneration of the retinal ganglion cells and their axons which form the optic nerve.
  • the ocular disease related to mitochondrial DNA (mtDNA) maintenance is foveopathy.
  • foveopathy refers to an atrophy of fovea. Fovea is a small, central pit composed of closely packed cones in the eye. It is located in the center of the macula lutea of the retina.
  • the ADOA is combined with a singular foveopathy.
  • the ocular disease related to mitochondrial DNA (mtDNA) maintenance is non-syndromic dominant optic atrophy.
  • the non- syndromic dominant optic atrophy is combined with a singular a foveopathy.
  • the ocular disease related to mitochondrial DNA (mtDNA) maintenance is inherited optic neuropathy.
  • the term“inherited optic neuropathy” covers a spectrum of clinically and genetically heterogenic conditions.
  • the inherited optic neuropathy is Leber hereditary optic neuropathy (LHON).
  • LHON is mainly characterized by bilateral, painless subacute loss of central vision during young adult life.
  • the inherited optic neuropathy is dominant optic atrophy OPA1.
  • the term“subject” denotes a mammal, such as a rodent, a feline, a canine, and a primate.
  • the subject according to the invention is a human. More particularly, the subject according to the invention has or is susceptible to have an ocular disease related to mtDNA maintenance.
  • the subject has or is susceptible to have Autosomal dominant optic atrophy (ADO A).
  • ADO A Autosomal dominant optic atrophy
  • the subject has or is susceptible to have ADOA accompanied with a foveopathy.
  • the subject has or is susceptible to have dominant optic atrophy OPA1.
  • the subject has or is susceptible to have dominant optic atrophy. In a particular embodiment, the subject has or is susceptible to have foveopathy.
  • the subject has or is susceptible to have dominant optic neuropathy accompanied with foveopathy
  • SSBP1 refers to single-stranded DNA-binding protein.
  • SSBP1 is a housekeeping gene involved in mitochondrial biogenesis. The gene SSBP1 encodes mitochondrial single-stranded DNA-binding protein and interacts with POLG and TWINKLE at the mitochondrial replication fork to stimulate synthesis of mtDNA (25).
  • SSBP1 binds to single-stranded mtDNA (ssmtDNA) as a tetramer and prevents re-annealing and nucleolytic attacks.
  • ssmtDNA single-stranded mtDNA
  • the naturally occurring human SSBP1 gene has a nucleotide sequence as shown in Genbank Accession numbers NM_001256510, NM_001256511, NM_001256512,
  • NM_001256513 and NM_003143 The naturally occurring human SSBP1 protein has an aminoacid sequence as shown in Genbank Accession numbers NP 001243439, NP_001243440, NP_001243441, NP_001243442 and NP_003134.
  • the term "gene” has its general meaning in the art and refers to means a DNA sequence that codes for or corresponds to a particular sequence of amino acids which comprise all or part of one or more proteins or enzymes, and may or may not include regulatory DNA sequences, such as promoter sequences, which determine for example the conditions under which the gene is expressed.
  • allele has its general meaning in the art and refers to an alternative form of a gene (one member of a pair) that is located at a specific position on a specific chromosome which, when translated result in functional or dysfunctional (including nonexistent) gene products.
  • SSBP1 protein has its general meaning in the art and refers to one or more long chains of amino acid residues which comprise all or part of one or more proteins or enzymes.
  • SSBP1 protein is involved in mtDNA replication and binds to single- stranded mtDNA (ssmtDNA) as a tetramer and prevents re-annealing and nucleolytic attacks.
  • RNA for“Ribonucleic acid” has its general meaning in the art and refers to a polymeric molecule essential in various biological roles in coding, decoding, regulation and expression of genes. Like DNA, RNA is assembled as a chain of nucleotides, but unlike DNA, RNA is found in nature as a single strand folded onto itself, rather than a paired double strand. RNA includes messenger RNA and non-coding RNAs such as transfer RNA, ribosomal RNA. Messenger RNA (mRNA) is the RNA that carries information from DNA to the ribosome, the sites of protein synthesis (translation) in the cell.
  • mRNA messenger RNA
  • the RNA expression level determined in step i) is messenger RNA (mRNA).
  • biological sample refers to any sample obtained from a subject, such as a serum sample, a plasma sample, a urine sample, a blood sample, a lymph sample, or a tissue biopsy.
  • biological sample for the determination of an expression level include samples such as a blood sample or a urine sample, lymph sample, or a biopsy.
  • the biological sample is a blood sample, more particularly, peripheral blood mononuclear cells (PBMC).
  • PBMC peripheral blood mononuclear cells
  • these cells can be extracted from whole blood using Ficoll, a hydrophilic polysaccharide that separates layers of blood, with the PBMC forming a cell ring under a layer of plasma.
  • PBMC can be extracted from whole blood using a hypotonic lysis, which will preferentially lyse red blood cells.
  • Inventors have shown that missense mutations in SSBP1, leading to the R38Q and R107Q amino-acid changes in the mitochondrial single-stranded DNA-binding protein, a crucial protein involved in mtDNA replication.
  • the method according to the invention wherein the mutation is C.113G>A and/or c.320G>A in the SSBP1 gene.
  • the method according to the invention wherein the mutation is R38Q and/or R107Q in the SSBP1 protein.
  • the present invention also relates to a method for predicting the risk of having or developing ocular disease related to mtDNA maintenance in a subject in need thereof, comprising the step of detecting SSBP1 single nucleotide polymorphism (SNP) in a biological sample obtained from said subject.
  • SNP single nucleotide polymorphism
  • the present invention relates to a method for predicting the risk of having or developing ocular disease related to mtDNA maintenance in a subject in need thereof, comprising the step of determining the expression level of SSBP1 and/or detecting SSBP1 SNP in a biological sample obtained from said subject.
  • the invention relates to a method for predicting the risk of having or developing ocular disease related to mtDNA maintenance in a subject in need thereof, comprising the steps of: i) determining the expression level of SSBP1 protein and/or detecting SSBP1 SNP in a biological sample obtained from said subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) concluding that the subject is at risk of having or developing ocular disease related to mtDNA maintenance when the expression level determined at step i) is lower than the predetermined reference value and/or when the SSBP1 SNP is detected, or concluding that the patient is not at risk of having or developing ocular disease related to mtDNA maintenance when the expression level determined at step i) is higher than the predetermined reference value and/or when the SNP is not detected.
  • the method according to the invention further comprising the steps of: i) identifying at least one mutation in the SSBP1 gene and/or protein; ii) concluding that the subject is at risk of having or developing ocular disease related to mtDNA maintenance when at least one mutation is identified.
  • mutation has its general meaning in the art and refers to any detectable change in genetic material, e.g. DNA, RNA, cDNA, or any process, mechanism, or result of such a change.
  • Mutations include deletion, insertion or substitution of one or more nucleotides. The mutation may occur in the coding region of a gene (i.e. in exons), in introns, or in the regulatory regions (e.g.
  • a mutation is identified in a subject by comparing the sequence of a nucleic acid or polypeptide expressed by said subject with the corresponding nucleic acid or polypeptide expressed in a control population. Where the mutation is within the gene coding sequence, the mutation may be a "missense” mutation, where it replaces one amino acid with another in the gene product, or a "non sense” mutation, where it replaces an amino acid codon with a stop codon. A mutation may also occur in a splicing site where it creates or destroys signals for exon-intron splicing and thereby lead to a gene product of altered structure. A mutation in the genetic material may also be "silent", i.e. the mutation does not result in an alteration of the amino acid sequence of the expression product.
  • homozygous refers to an individual possessing two copies of the same allele.
  • homozygous mutant refers to an individual possessing two copies of the same allele, such allele being characterized as the mutant form of a gene.
  • the term "heterozygous” refers to an individual possessing two different alleles of the same gene, i.e. an individual possessing two different copies of an allele, such alleles are characterized as mutant forms of a gene.
  • the mutation allows to a truncated protein.
  • truncated protein refers to a protein shortened by a mutation which specifically induces premature termination of messenger RNA translation.
  • single nucleotide polymorphism refers to is a single basepair variation in a nucleic acid sequence of SSBP1 gene.
  • Polymorphisms can be referred to, for instance, by the nucleotide position at which the variation exists, by the change in amino acid sequence caused by the nucleotide variation, or by a change in some other characteristic of the nucleic acid molecule that is linked to the variation (e.g., an alteration of a secondary structure such as a stem-loop, or an alteration of the binding affinity of the nucleic acid for associated molecules, such as polymerases, RNases, and so forth).
  • the SNP in the context of the invention is missense mutation in exon 1 and exon 4 leading to the G113A in exon 4 and/or G320A substitution in SSBP1.
  • the presence or absence of a SNP can be determined by nucleic acid sequencing, PCR analysis or any genotyping method known in the art such as the method described in the example.
  • methods include, but are not limited to, chemical assays such as allele specific hybridization (DASH), pyrosequencing, molecular beacons, SNP microarrays, restriction fragment length polymorphism (RFLP), flap endonuclease (FEN), single strand conformation polymorphism, temperature gradient gel electrophoresis (TGGE), denaturing high performance liquid chromatography (DHPLC), high-resolution melting of the entire amplicon, and DNA mismatch-binding proteins primer extension, allele specific oligonucleotide ligation, sequencing, enzymatic cleavage, flap endonuclease discrimination; and detection methods such as fluorescence, chemiluminescence, and mass spectrometry.
  • DASH allele specific hybridization
  • RFLP restriction fragment length polymorphism
  • FEN flap
  • the presence or absence of said polymorphism may be detected in a DNA sample, preferably after amplification.
  • the isolated DNA may be subjected to couple reverse transcription and amplification, such as reverse transcription and amplification by polymerase chain reaction (RT-PCR), using specific oligonucleotide primers that are specific for the polymorphism or that enable amplification of a region containing the polymorphism.
  • RT-PCR polymerase chain reaction
  • conditions for primer annealing may be chosen to ensure specific reverse transcription (where appropriate) and amplification; so that the appearance of an amplification product be a diagnostic of the presence of the polymorphism according to the invention.
  • DNA may be amplified, after which a mutated site may be detected in the amplified sequence by hybridization with a suitable probe or by direct sequencing, or any other appropriate method known in the art.
  • nucleic acid molecule may be tested for the presence or absence of a restriction site.
  • a base polymorphism creates or abolishes the recognition site of a restriction enzyme, this allows a simple direct PCR genotype the polymorphism.
  • Further strategies include, but are not limited to, direct sequencing, restriction fragment length polymorphism (RFLP) analysis; hybridization with allele-specific oligonucleotides (ASO) that are short synthetic probes which hybridize only to a perfectly matched sequence under suitably stringent hybridization conditions; allele specific PCR; PCR using mutagenic primers; ligase-PCR, HOT cleavage; denaturing gradient gel electrophoresis (DGGE), temperature denaturing gradient gel electrophoresis (TGGE), single-stranded conformational polymorphism (SSCP) and denaturing high performance liquid chromatography (Kuklin et al., 1997).
  • RFLP restriction fragment length polymorphism
  • ASO allele-specific oligonucleotides
  • Direct sequencing may be accomplished by any method, including without limitation chemical sequencing, using the Maxam-Gilbert method; by enzymatic sequencing, using the Sanger method; mass spectrometry sequencing; pyrosequencing; sequencing using a chip-based technology and real-time quantitative PCR.
  • DNA from a patient is first subjected to amplification by polymerase chain reaction (PCR) using specific amplification primers.
  • PCR polymerase chain reaction
  • PCR polymerase chain reaction
  • RCA rolling circle amplification
  • Invader TMassay the Invader TMassay
  • OLA oligonucleotide ligation assay
  • oligonucleotides are constructed that hybridize to adjacent sequences in the target nucleic acid, with the join sited at the position of the polymorphism.
  • DNA ligase will covalently join the two oligonucleotides only if they are perfectly hybridized to one of the allele.
  • Oligonucleotide probes or primers may contain at least 10, 15, 20 or 30 nucleotides. Their length may be shorter than 400, 300, 200 or 100 nucleotides.
  • the determination of the presence or absence of said SNP may also be determined by detection or not of the mutated protein by any method known in the art.
  • the presence of the protein of interest may be detected using standard electrophoretic and immunodiagnostic techniques, including immunoassays such as competition, direct reaction, or sandwich type assays.
  • immunoassays include, but are not limited to, Western blots; agglutination tests; enzyme-labelled and mediated immunoassays, such as ELISAs; biotin/avidin type assays; radioimmunoassays; immunoelectrophoresis; immunoprecipitation, etc.
  • the reactions generally include revealing labels such as fluorescent, chemiluminescent, radioactive, enzymatic labels or dye molecules, or other methods for detecting the formation of a complex between the antigen and the antibody or antibodies reacted therewith.
  • Labels are known in the art that generally provide (either directly or indirectly) a signal.
  • the term “labelled” with regard to the antibody or aptamer is intended to encompass direct labelling of the antibody or aptamer by coupling (i.e., physically linking) a detectable substance, such as a radioactive agent or a fluorophore (e.g.
  • FITC fluorescein isothiocyanate
  • PE phycoerythrin
  • Cy5 indocyanine
  • An antibody or aptamer may be also labelled with a radioactive molecule by any method known in the art.
  • radioactive molecules include but are not limited radioactive atom for scintigraphic studies such as 1123, 1124, Ini 11, Rel86 and Rel88.
  • the aforementioned assays generally involve separation of unbound protein in a liquid phase from a solid phase support to which antigen-antibody complexes are bound.
  • Solid supports which may be used in the practice of the invention include substrates such as nitrocellulose (e.g., in membrane or microtiter well form); polyvinylchloride (e.g., sheets or microtiter wells); polystyrene latex (e.g., beads or microtiter plates); polyvinylidine fluoride; diazotized paper; nylon membranes; activated beads, magnetically responsive beads, etc. More particularly, an ELISA method may be used, wherein the wells of a microtiter plate are coated with an antibody against the protein to be tested. A biological sample containing or suspected of containing the marker protein is then added to the coated wells.
  • substrates such as nitrocellulose (e.g., in membrane or microtiter well form); polyvinylchloride (e.g., sheets or microtiter wells); polystyrene latex (e.g., beads or microtiter plates); polyvinylidine fluoride; diazotized paper; nylon
  • the plate (s) can be washed to remove unbound moieties and a detectably labelled secondary binding molecule added.
  • the secondary binding molecule is allowed to react with any captured sample marker protein, the plate washed and the presence of the secondary binding molecule detected using methods well known in the art.
  • IHC immunohistochemistry
  • a biological sample or tissue specimen in situ.
  • the overall cellular integrity of the sample is maintained in IHC, thus allowing detection of both the presence and location of the target of interest.
  • a biological sample is fixed with formalin, embedded in paraffin and cut into sections for staining and subsequent inspection by light microscopy.
  • Current methods of IHC use either direct labeling or secondary antibody- based or hapten-based labeling.
  • IHC systems examples include, for example, EnVisionTM (DakoCytomation), Powervision® (Immunovision, Springdale, AZ), the NBATM kit (Zymed Laboratories Inc., South San Francisco, CA), HistoFine® (Nichirei Corp, Tokyo, Japan).
  • direct sequencing of the whole genome is used to detect the SNP locus SSBP1.
  • the whole genome sequencing may be achieved by use of the next generation sequencing (NGS) assay.
  • NGS next generation sequencing
  • a single genomic DNA is first fragmented into a library of small segments that can be uniformly and accurately sequenced in millions of parallel reactions.
  • the newly identified strings of bases, called reads are then reassembled using a known reference genome as a scaffold (resequencing), or in the absence of a reference genome (de novo sequencing).
  • the full set of aligned reads would reveal the entire sequence of each chromosome of the genomic DNA.
  • primer extension assay is used to detect the SNP locus SSBP1.
  • the primer extension assay may be achieved by use of Matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS).
  • MALDI-TOF MS Matrix assisted laser desorption ionization time-of-flight mass spectrometry
  • Mass spectrometry is an experimental technique used to identify the components of a heterogeneous collection of biomolecules, by sensitive discrimination of their molecular masses.
  • MALTI- TOF MS the sample to be analyzed is placed in a UV-absorbing matrix pad and exposed to a short laser pulse. The ionized molecules are accelerated off the matrix pad (i.e., desorption) and move into an electric field towards a detector.
  • The“time of flight” required to reach the detector depends on the mass/charge (m/z) ratio of the individual molecules.
  • MALTI-TOF MS mass/charge MS for DNA sequencing
  • the DNA sequence to be sampled is first transcribed into RNA in vitro in 4 separate reactions, each with three rNTP bases and one specific dNTP.
  • the incorporated dNTP in the transcribed RNA will prevent cleavage from occurring at that dNTP position by RNAse, and therefore generate distinct fragments.
  • Each fragment has a characteristic m/z ratio that appears as a peak in MALTI-TOF spectrum.
  • the MALTI-TOF mass signal pattern obtained for the DNA sample is then compared with the expected m/z spectrum of the reference sequence, which includes the products of all 4 cleavage reactions. Any SNP differences between the sample DNA and the reference DNA sequences will produce predictable shifts in the spectrum, and their exact nature can be deduced.
  • qPCR quantitative polymerase chain reaction
  • DNA sample that includes the SNP locus is amplified and simultaneously detected and quantitated with different primer sets that target each allele separately.
  • Well-designed primers will amplify their target SNP at a much earlier cycle than the other SNPs. This allows more than two alleles to be distinguished, although an individual qPCR reaction is required for each SNP.
  • the primer sequence may require placement of an artificial mismatch near its 3 '-end, which is an approach generally known as Taq-MAMA. This artificial mismatch induces a much greater amplification delay for non-target alleles than a single mismatch would alone, yet does not substantially affect amplification of the target SNP.
  • the SNP locus is detected by direct sequencing of a specified DNA segment containing the SNP locus of SSBP1.
  • the term“expression level” refers to the expression level of SSBP1 with further other values corresponding to the clinical parameters.
  • the expression level of the gene may be determined by any technology known by a person skilled in the art.
  • each gene expression level may be measured at the genomic and/or nucleic and/or protein level.
  • the expression level of SSBPlgene is measured.
  • the expression level of SSBP1 is assessed by analyzing the expression of the protein translated from said gene.
  • Said analysis can be assessed using an antibody (e.g., a radio-labelled, chromophore- labelled, fluorophore-labelled, or enzyme-labelled antibody), an antibody derivative (e.g., an antibody conjugate with a substrate or with the protein or ligand of a protein of a protein/ligand pair (e.g., biotin-streptavidin)), or an antibody fragment (e.g., a single-chain antibody, an isolated antibody hypervariable domain, etc.) which binds specifically to the protein translated from the gene encoding for SSBP1.
  • an antibody e.g., a radio-labelled, chromophore- labelled, fluorophore-labelled, or enzyme-labelled antibody
  • an antibody derivative e.g., an antibody conjugate with a substrate or with the protein or ligand of a protein of a protein/ligand pair (e.g., biotin-streptavidin)
  • an antibody fragment e.g.,
  • Methods for measuring the expression level of SSBP1 in a sample may be assessed by any of a wide variety of well-known methods from one of skill in the art for detecting expression of a protein including, but not limited to, direct methods like mass spectrometry-based quantification methods, protein microarray methods, enzyme immunoassay (EIA), radioimmunoassay (RIA), Immunohistochemistry (IHC), Western blot analysis, ELISA, Luminex, ELISPOT and enzyme linked immunosorbent assay and indirect methods based on detecting expression of corresponding messenger ribonucleic acids (mRNAs).
  • the mRNA expression profile may be determined by any technology known by a man skilled in the art.
  • each mRNA expression level may be measured using any technology known by a man skilled in the art, including nucleic microarrays, quantitative Polymerase Chain Reaction (qPCR), next generation sequencing and hybridization with a labelled probe.
  • the binding partner may be an antibody that may be polyclonal or monoclonal, preferably monoclonal (e.g., a isotope-label, element-label, radio-labelled, chromophore- labelled, fluorophore-labelled, or enzyme-labelled antibody), an antibody derivative (e.g., an antibody conjugate with a substrate or with the protein or ligand of a protein of a protein/ligand pair (e.g., biotin-streptavidin)), or an antibody fragment (e.g., a single-chain antibody, an isolated antibody hypervariable domain, etc.) which binds specifically to the protein translated from the gene encoding for the biomarker of the invention.
  • the binding partner may be an aptamer.
  • binding partners of the invention such as antibodies or aptamers, may be labelled with a detectable molecule or substance, such as an isotope, an element, a fluorescent molecule, a radioactive molecule or any others labels known in the art.
  • a detectable molecule or substance such as an isotope, an element, a fluorescent molecule, a radioactive molecule or any others labels known in the art.
  • Labels are known in the art that generally provide (either directly or indirectly) a signal.
  • the term "labelled", with regard to the antibody is intended to encompass direct labelling of the antibody or aptamer by coupling (i.e., physically linking) a detectable substance, such as an isotope, an element, a radioactive agent or a fluorophore (e.g. fluorescein isothiocyanate (FITC) or phycoerythrin (PE) or Indocyanine (Cy5)) to the antibody or aptamer, as well as indirect labelling of the probe or antibody by reactivity with a detectable substance.
  • a detectable substance such as an isotope, an element, a radioactive agent or a fluorophore (e.g. fluorescein isothiocyanate (FITC) or phycoerythrin (PE) or Indocyanine (Cy5)
  • FITC fluorescein isothiocyanate
  • PE phycoerythrin
  • Indocyanine Indocyanine
  • radioactive molecules include but are not limited to radioactive atom for scintigraphy studies such as 1123, 1124, Ini 11, Rel86, Rel88, specific isotopes include but are not limited to 13C, 15N, 1261, 79Br, 81Br.
  • the aforementioned assays generally involve the binding of the binding partner (ie. antibody or aptamer) to a solid support.
  • Solid supports which can be used in the practice of the invention include substrates such as nitrocellulose (e. g., in membrane or microtiter well form); polyvinylchloride (e.
  • polystyrene latex e.g., beads or microtiter plates
  • polyvinylidene fluoride e.g., diazotized paper
  • nylon membranes e.g., nylon membranes
  • an ELISA method can be used, wherein the wells of a microtiter plate are coated with a set of antibodies which recognize SSBP1 protein. A sample containing or suspected of containing said biomarker is then added to the coated wells. After a period of incubation sufficient to allow the formation of antibody-antigen complexes, the plate(s) can be washed to remove unbound moieties and a detectably labelled secondary binding molecule added. The secondary binding molecule is allowed to react with any captured sample marker protein, the plate washed and the presence of the secondary binding molecule detected using methods well known in the art such as Singulex, Quanterix, MSD, Bioscale, Cytof.
  • an Enzyme-linked immunospot (ELISpot) method may be used.
  • the sample is transferred to a plate which has been coated with the desired anti- SSBP1 protein capture antibodies.
  • Revelation is carried out with biotinylated secondary Abs and standard colorimetric or fluorimetric detection methods such as streptavidin-alkaline phosphatase and NBT-BCIP and the spots counted.
  • the bead may be a cytometric bead for use in flow cytometry.
  • Such beads may for example correspond to BDTM Cytometric Beads commercialized by BD Biosciences (San Jose, California).
  • cytometric beads may be suitable for preparing a multiplexed bead assay.
  • a multiplexed bead assay such as, for example, the BD(TM) Cytometric Bead Array, is a series of spectrally discrete beads that can be used to capture and quantify soluble antigens.
  • beads are labelled with one or more spectrally distinct fluorescent dyes, and detection is carried out using a multiplicity of photodetectors, one for each distinct dye to be detected.
  • a number of methods of making and using sets of distinguishable beads have been described in the literature. These include beads distinguishable by size, wherein each size bead is coated with a different target-specific antibody (see e.g. Fulwyler and McHugh, 1990, Methods in Cell Biology 33 :613-629), beads with two or more fluorescent dyes at varying concentrations, wherein the beads are identified by the levels of fluorescence dyes (see e.g. European Patent No.
  • beads distinguishably labelled with two different dyes, wherein the beads are identified by separately measuring the fluorescence intensity of each of the dyes (see e.g. U.S. patent Nos. 4,499,052 and 4,717,655).
  • Both one-dimensional and two-dimensional arrays for the simultaneous analysis of multiple antigens by flow cytometry are available commercially. Examples of one-dimensional arrays of singly dyed beads distinguishable by the level of fluorescence intensity include the BD(TM) Cytometric Bead Array (CBA) (BD Biosciences, San Jose, Calif.) and Cyto-Plex(TM) Flow Cytometry microspheres (Duke Scientific, Palo Alto, Calif.).
  • An example of a two-dimensional array of beads distinguishable by a combination of fluorescence intensity (five levels) and size (two sizes) is the QuantumPlex(TM) microspheres (Bangs Laboratories, Fisher, Ind.).
  • An example of a two- dimensional array of doubly-dyed beads distinguishable by the levels of fluorescence of each of the two dyes is described in Fulton et al. (1997, Clinical Chemistry 43(9): 1749-1756).
  • the beads may be labelled with any fluorescent compound known in the art such as e.g. FITC (FL1), PE (FL2), fluorophores for use in the blue laser (e.g.
  • bead is a magnetic bead for use in magnetic separation. Magnetic beads are known to those of skill in the art. Typically, the magnetic bead is preferably made of a magnetic material selected from the group consisting of metals (e.g. ferrum, cobalt and nickel), an alloy thereof and an oxide thereof. In another particular embodiment, bead is bead that is dyed and magnetized.
  • metals e.g. ferrum, cobalt and nickel
  • bead is bead that is dyed and magnetized.
  • protein microarray methods may be used.
  • at least one antibody or aptamer directed against SSBP1 protein is immobilized or grafted to an array(s), a solid or semi-solid surface(s).
  • a sample containing or suspected of containing SSBP1 protein is then labelled with at least one isotope or one element or one fluorophore or one colorimetric tag that are not naturally contained in the tested sample.
  • the array is then washed and dried.
  • quantifying SSBP1 protein may be achieved by using any appropriate microarray scanner like fluorescence scanner, colorimetric scanner, SIMS (secondary ions mass spectrometry) scanner, maldi scanner, electromagnetic scanner or any technique allowing to quantify said labels.
  • any appropriate microarray scanner like fluorescence scanner, colorimetric scanner, SIMS (secondary ions mass spectrometry) scanner, maldi scanner, electromagnetic scanner or any technique allowing to quantify said labels.
  • the antibody or aptamer grafted on the array is labelled.
  • reverse phase arrays may be used.
  • at least one sample is immobilized or grafted to an array(s), a solid or semi-solid surface(s).
  • An antibody or aptamer against the suspected biomarker is then labelled with at least one isotope or one element or one fluorophore or one colorimetric tag that are not naturally contained in the tested sample.
  • the array is then washed and dried.
  • detecting quantifying and counting by D-SIMS said biomarker containing said isotope or group of isotopes, and a reference natural element, and then calculating the isotopic ratio between the biomarker and the reference natural element may be achieve using any appropriate microarray scanner like fluorescence scanner, colorimetric scanner, SIMS (secondary ions mass spectrometry) scanner, maldi scanner, electromagnetic scanner or any technique allowing to quantify said labels.
  • any appropriate microarray scanner like fluorescence scanner, colorimetric scanner, SIMS (secondary ions mass spectrometry) scanner, maldi scanner, electromagnetic scanner or any technique allowing to quantify said labels.
  • said direct analysis can also be assessed by mass Spectrometry.
  • Mass spectrometry-based quantification methods may be performed using either labelled or unlabelled approaches (DeSouza and Siu, 2012). Mass spectrometry-based quantification methods may be performed using chemical labeling, metabolic labelingor proteolytic labeling. Mass spectrometry-based quantification methods may be performed using mass spectrometry label free quantification, LTQ Orbitrap Velos, LTQ-MS/MS, a quantification based on extracted ion chromatogram EIC (progenesis LC-MS, Liquid chromatography-mass spectrometry) and then profile alignment to determine differential expression of the biomarker.
  • the SSBP1 expression level is assessed by analyzing the expression of mRNA transcript or mRNA precursors, such as nascent RNA, of SSBP1 gene. Said analysis can be assessed by preparing mRNA/cDNA from cells in a sample from a subject, and hybridizing the mRNA/cDNA with a reference polynucleotide. The prepared mRNA/cDNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses, such as quantitative PCR (TaqMan), and probes arrays such as GeneChip(TM) DNA Arrays ( AFF YMETRIX) .
  • mRNA transcript or mRNA precursors such as nascent RNA
  • the analysis of the expression level of mRNA transcribed from the gene encoding for biomarkers involves the process of nucleic acid amplification, e. g., by RT- PCR (the experimental embodiment set forth in U. S. Patent No. 4,683, 202), ligase chain reaction (Barany, 1991), self- sustained sequence replication (Guatelli et ah, 1990), transcriptional amplification system (Kwoh et ah, 1989), Q-Beta Replicase (Lizardi et al., 1988), rolling circle replication (U. S. Patent No.
  • amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between.
  • amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.
  • the term“predetermined reference value” refers to a threshold value or a cut-off value.
  • the setting of a single“reference value” thus allows discrimination between a subject at risk of having or developing IA and a subject not at risk of having or developing IA with respect to the overall survival (OS) for a subject.
  • OS overall survival
  • a “threshold value” or “cut off value” can be determined experimentally, empirically, or theoretically.
  • a threshold value can also be arbitrarily selected based upon the existing experimental and/or clinical conditions, as would be recognized by a person of ordinary skilled in the art. The threshold value has to be determined in order to obtain the optimal sensitivity and specificity according to the function of the test and the benefit/risk balance (clinical consequences of false positive and false negative).
  • the optimal sensitivity and specificity can be determined using a Receiver Operating Characteristic (ROC) curve based on experimental data.
  • ROC Receiver Operating Characteristic
  • the person skilled in the art may compare the expression level (obtained according to the method of the invention) with a defined threshold value.
  • the threshold value is derived from the expression level (or ratio, or score) determined in a biological sample derived from one or more subjects at risk of having or developing IA.
  • retrospective measurement of the expression level (or ratio, or scores) in properly banked historical subject samples may be used in establishing these threshold values.
  • Predetermined reference values used for comparison may comprise “cut-off’ or “threshold” values that may be determined as described herein.
  • Each reference (“cut-off’) value for SSBP1 may be predetermined by carrying out a method comprising the steps of
  • the expression level of SSBP1 has been assessed for 100 samples of 100 patients.
  • the 100 samples are ranked according to their expression level.
  • Sample 1 has the best expression level and sample 100 has the worst expression level.
  • a first grouping provides two subsets: on one side sample Nr 1 and on the other side the 99 other samples.
  • the next grouping provides on one side samples 1 and 2 and on the other side the 98 remaining samples etc., until the last grouping: on one side samples 1 to 99 and on the other side sample Nr 100.
  • Kaplan Meier curves are prepared for each of the 99 groups of two subsets. Also for each of the 99 groups, the p value between both subsets was calculated.
  • the reference value is selected such as the discrimination based on the criterion of the minimum p value is the strongest.
  • the expression level corresponding to the boundary between both subsets for which the p value is minimum is considered as the reference value. It should be noted that the reference value is not necessarily the median value of expression levels.
  • the reference value (cut-off value) may be used in the present method to discriminate samples and therefore the corresponding patients.
  • Kaplan-Meier curves of percentage of survival as a function of time are commonly to measure the fraction of patients living for a certain amount of time after treatment and are well known by the man skilled in the art.
  • the reference value may correspond to the expression level of SSBP1 determined in a sample associated with subject at risk of having or developing ocular disease related to mtDNA maintenance. Accordingly, a lower expression level of SSBP1 than the reference value is indicative of a subject at risk of having or developing ocular disease related to mtDNA maintenance, and a higher or equal expression level of SSBP1 than the reference value is indicative of a subject not at risk of having or developing acute ocular disease related to mtDNA maintenance.
  • the reference value may correspond to the expression level of SSBP1 determined in a sample associated with subject not at risk of having or developing ocular disease related to mtDNA maintenance. Accordingly, a higher or equal expression level of SSBP1 than the reference value is indicative of a subject not at risk of having or developing ocular disease related to mtDNA maintenance, and a lower expression level of SSBP1 than the reference value is indicative of a subject at risk of having or developing ocular disease related to mtDNA maintenance.
  • the invention in a second aspect, relates to a method for treating ocular disease related to mtDNA maintenance in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an inhibitor of mutations in SSBP1 gene.
  • the method according to the invention wherein the mutations lead to the R38Q and R107Q amino-acid changes in the mitochondrial single- stranded DNA-binding protein.
  • the invention relates to a method for treating ocular disease related to mtDNA maintenance in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an inhibitor of mutated SSBP1 gene.
  • the terms“treating” or“treatment” refer to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of subject at risk of contracting the disease or suspected to have contracted the disease as well as subject who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
  • the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
  • therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
  • a therapeutic regimen may include an induction regimen and a maintenance regimen.
  • the phrase “induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
  • the general goal of an induction regimen is to provide a high level of drug to a subject during the initial period of a treatment regimen.
  • An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
  • maintenance regimen refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a subject during treatment of an illness, e.g., to keep the subject in remission for long periods of time (months or years).
  • a maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., pain, disease manifestation, etc.]).
  • inhibitor refers to a natural or synthetic compound able to inhibit the activity and/or expression of mutated SSBP1.
  • mutated SSBP1 activity refers to unstable formation of SSBP1 dimer/tetramer affecting mtDNA replication leading to a decrease of mtDNA copy- number.
  • mutated SSBP1 expression refers to SSBP1 gene comprising a missense mutation leading to the R38Q and R107Q amino-acid changes in the mitochondrial single-stranded DNA-binding protein.
  • the missense mutation is c. H3G>A and/or c.320G>A in the SSBP1 gene.
  • the missense mutation is R38Q and/or R107Q in the SSBP1 protein.
  • the inhibitor of SSBP1 is an inhibitor of mutated SSBP1 expression.
  • an “inhibitor of mutated SSBP1 expression” refers to a natural or synthetic compound that has a biological effect to inhibit or significantly reduce the expression of the mutated gene encoding for a truncated and inactive SSBP1.
  • the inhibitor of mutated SSBP1 gene expression has a biological effect on one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5' cap formation, and/or 3' end formation); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.
  • the method according to the invention wherein the inhibitor of mutated SSBP1 gene expression is siRNA, shRNA, miRNA, antisense oligonucleotide, or a ribozyme.
  • the inhibitor of mutated SSBP1 expression is an antisense oligonucleotide.
  • Anti-sense oligonucleotides including anti-sense RNA molecules and anti- sense DNA molecules, would act to directly block the translation of SSBP1 mRNA by binding thereto and thus preventing protein translation or increasing mRNA degradation, thus decreasing the level of SSBP1 proteins, and thus activity, in a cell.
  • antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the mRNA transcript sequence encoding SSBP1 can be synthesized, e.g., by conventional phosphodiester techniques and administered by e.g., intravenous, subcutaneous or intravitreal injection.
  • the inhibitor of mutated SSBP1 expression is a shRNA.
  • shRNA is generally expressed using a vector introduced into cells, wherein the vector utilizes the U6 promoter to ensure that the shRNA is always expressed. This vector is usually passed on to daughter cells, allowing the gene silencing to be inherited.
  • the shRNA hairpin structure is cleaved by the cellular machinery into siRNA, which is then bound to the RNA-induced silencing complex (RISC). This complex binds to and cleaves mRNAs that match the siRNA to which it is bound.
  • RISC RNA-induced silencing complex
  • the inhibitor of mutated SSBP1 expression is a small inhibitory RNAs (siRNAs).
  • SSBP1 expression can be reduced by contacting the subject or cell with a small double stranded RNA (dsRNA), or a vector or construct causing the production of a small double stranded RNA, such that SSBP1 expression is specifically inhibited (i.e. RNA interference or RNAi).
  • dsRNA small double stranded RNA
  • RNAi RNA interference
  • Methods for selecting an appropriate dsRNA or dsRNA-encoding vector are well known in the art for genes whose sequence is known (e.g. see Tuschl, T. et al. (1999); Elbashir, S. M. et al. (2001); Hannon, GJ. (2002); McManus, MT.
  • the siRNA is ALN-PCS02 developed by Alnylam (phase 1 ongoing).
  • the inhibitor of mutated SSBP1 expression is a ribozyme. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
  • ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
  • Engineered hairpin or hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of SSBP1 mRNA sequences are thereby useful within the scope of the present invention.
  • Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which typically include the following sequences, GUA, GUU, and GUC.
  • RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render the oligonucleotide sequence unsuitable.
  • the suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using, e.g., ribonuclease protection assays.
  • the inhibitor of mutated SSBP1 expression is an endonuclease.
  • endonuclease refers to enzymes that cleave the phosphodiester bond within a polynucleotide chain. Some, such as Deoxyribonuclease I, cut DNA relatively nonspecifically (without regard to sequence), while many, typically called restriction endonucleases or restriction enzymes, and cleave only at very specific nucleotide sequences.
  • endonuclease-based genome inactivating generally requires a first step of DNA single or double strand break, which can then trigger two distinct cellular mechanisms for DNA repair, which can be exploited for DNA inactivating: the errorprone nonhomologous end-joining (NHEJ) and the high-fidelity homology-directed repair (HDR).
  • NHEJ errorprone nonhomologous end-joining
  • HDR high-fidelity homology-directed repair
  • the endonuclease is CRISPR-cas.
  • CRISPR-cas has its general meaning in the art and refers to clustered regularly interspaced short palindromic repeats associated which are the segments of prokaryotic DNA containing short repetitions of base sequences.
  • the endonuclease is CRISPR-cas9 which is from Streptococcus pyogenes.
  • the CRISPR/Cas9 system has been described in US 8697359 B1 and US 2014/0068797.
  • the endonuclease is CRISPR-Cpfl which is the more recently characterized CRISPR from Provotella and Francisella 1 (Cpfl) in Zetsche et al. (“Cpfl is a Single RNA- guided Endonuclease of a Class 2 CRISPR-Cas System (2015); Cell; 163, 1-13).
  • administering refers to the act of injecting or otherwise physically delivering a substance as it exists outside the body (e.g., an inhibitor of SSBPlexpression/activity) into the subject, such as by, intravitreal, intravenous, subcutaneous, and/or any other method of physical delivery described herein or known in the art.
  • a disease, or a symptom thereof is being treated, administration of the substance typically occurs after the onset of the disease or symptoms thereof.
  • administration of the substance typically occurs before the onset of the disease or symptoms thereof.
  • a “therapeutically effective amount” is meant a sufficient amount of an inhibitor of SSBP1 expression and/or activity for use in a method for the treatment of ocular disease related to mtDNA maintenance at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts.
  • the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
  • the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic 20 adjustment of the dosage to the subject to be treated.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, typically from 1 mg to about 100 mg of the active ingredient.
  • An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
  • the invention relates to a method of treating ocular disease related to mtDNA maintenance in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for SSBP1.
  • a vector which comprises a nucleic acid molecule encoding for SSBP1.
  • the method according to the invention wherein the nucleic acid molecule encoding for a SSBP1 polypeptide comprising an amino acid sequence having at least 90% of identity with the sequence as set forth in SEQ ID NO: 1 :
  • the method according to the invention wherein the nucleic acid molecule is operatively linked to a promoter sequence.
  • the method according to the invention wherein the vector is a viral vector.
  • the method according to the invention wherein the viral vector is lentivirus (LV).
  • LV lentivirus
  • lentivirus refers to enveloped RNA particles measuring approximately 120 nm in size are efficient drug delivery tools and more particularly gene delivery tools.
  • the LV binds to, and enters into target cells through its envelope proteins which confer its pseudotype. Once the LV has entered into the cells, it releases its capsid components and undergoes reverse transcription of the lentiviral RNA before integrating the proviral DNA into the genome of target cells.
  • Non-integrative lentiviral vectors have been generated by modifying the properties of the vector integration machinery and can be used for transient gene expression.
  • Virus-like particles lacking a provirus have also been generated and can be used to deliver proteins or messenger RNA.
  • LV can be used for example, for gene addition, RNA interference, exon skipping or gene editing. All of these approaches can be facilitated by tissue or cell targeting of the LV via its pseudotype.
  • Lentivirus-like particles are described for example in Muratori et ah, Methods Mol. Biol., 2010, 614, 1 11-24; Burney et al, Curr. HIV Res., 2006, 4, 475-484; Kaczmarczyk et al, Proc Natl Acad Sci U S A., 2011, 108, 16998-17003; Aoki et al., Gene Therapy, 2011, 18, 936- 941.
  • Examples of lentivirus-like particles are VLPs generated by co-expressing in producer cells, a syncytin protein with a gag fusion protein (Gag fused with the gene of interest).
  • the drug and/or syncytin may be, either displayed on the surface of the particles, or enclosed (packaged) into the particles.
  • the syncytin protein is advantageously displayed on the surface of the particles, such as coupled to the particles or incorporated into the envelope of (enveloped) virus particles or virus-like particles to form pseudotyped enveloped virus particles or virus like particles.
  • the drug is coupled to the particles or packaged into the particles.
  • the drug is coupled to viral capsids or packaged into viral capsids, wherein said viral capsids may further comprise an envelope, preferably pseudotyped with syncytin.
  • the drug is packaged into the particles pseudotyped with syncytin protein.
  • the drug which is packaged into particles is advantageously a heterologous gene of interest which is packaged into viral vector particles, preferably retroviral vector particles, more preferably lenti viral vector particles.
  • the method according to the invention wherein the viral vector is adenovirus.
  • adenovirus refers to medium- sized (90-100 nm), nonenveloped (without an outer lipid bilayer) viruses with an icosahedral nucleocapsid containing a double stranded DNA genome.
  • the method according to the invention wherein the viral vector is an adeno-associated virus (AAV) vector.
  • AAV adeno-associated virus
  • AAV has its general meaning in the art and is an abbreviation for adeno-associated virus, and may be used to refer to the virus itself or derivatives thereof. The term covers all serotypes and variants both naturally occurring and engineered forms.
  • AAV refers to AAV type 1 (AAV-1), AAV type 2 (AAV- 2), AAV type 3 (AAV-3), AAV type 4 (AAV-4), AAV type 5 (AAV-5), AAV type 6 (AAV- 6), AAV type 7 (AAV-7), and AAV type 8 (AAV-8) and AAV type 9 (AAV9).
  • rAAV vector refers to an AAV vector comprising the polynucleotide of interest (i.e the polynucleotide encoding for the SSBP1 polypeptide).
  • the rAAV vectors contain 5' and 3' adeno-associated virus inverted terminal repeats (ITRs), and the polynucleotide of interest operatively linked to sequences, which regulate its expression in a target cell.
  • the AAV vector of the present invention typically comprises regulatory sequences allowing expression and, secretion of the encoded polypeptide (i.e. the SSBP1 polypeptide), such as e.g., a promoter, enhancer, polyadenylation signal, internal ribosome entry sites (IRES), sequences encoding protein transduction domains (PTD), and the like.
  • the vector comprises a promoter region, operably linked to the polynucleotide of interest, to cause or improve expression of the protein in infected cells.
  • a promoter may be ubiquitous, tissue- specific, strong, weak, regulated, chimeric, inducible, etc., to allow efficient and suitable production of the protein in the infected tissue.
  • the promoter may be homologous to the encoded protein, or heterologous, including cellular, viral, fungal, plant or synthetic promoters.
  • regulated promoters include, without limitation, Tet on/off element- containing promoters, rapamycin-inducible promoters and metallothionein promoters.
  • ubiquitous promoters include viral promoters, particularly the CMV promoter, CAG promoter (chicken beta actin promoter with CMV enhancer), the RS V promoter, the S V40 promoter, etc. and cellular promoters such as the PGK (phosphoglycerate kinase) promoter.
  • the promoters may also be neurospecific promoters such as the Synapsin or the NSE (Neuron Specific Enolase) promoters (or NRSE (Neuron restrictive silencer element) sequences placed upstream from the ubiquitous PGK promoter), or promoters specific for RPE cell types such as the RPE65, the BEST1, the Rhodopsin or the cone arrestin promoters.
  • the vector may also comprise target sequences for miRNAs achieving suppression of transgene expression in non ⁇ - desired cells.
  • the vector comprises a leader sequence allowing secretion of the encoded protein.
  • Fusion of the polynucleotide of interest with a sequence encoding a secretion signal peptide will allow the production of the therapeutic protein in a form that can be secreted from the transduced cells.
  • signal peptides include the albumin, the b-glucuronidase, the alkaline protease or the fibronectin secretory signal peptides.
  • the recombinant AAV vector of the present invention is produced using methods well known in the art.
  • the methods generally involve (a) the introduction of the rAAV vector into a host cell, (b) the introduction of an AAV helper construct into the host cell, wherein the helper construct comprises the viral functions missing from the rAAV vector and (c) introducing a helper virus into the host cell. All functions for rAAV virion replication and packaging need to be present, to achieve replication and packaging of the rAAV vector into rAAV virions.
  • the introduction into the host cell can be carried out using standard virological techniques simultaneously or sequentially.
  • the host cells are cultured to produce rAAV virions and are purified using standard techniques such as CsCl gradients. Residual helper virus activity can be inactivated using known methods, such as for example heat inactivation.
  • the purified rAAV vector is then ready for use in the method of the present invention.
  • the method according to the invention wherein the AAV vector is selected from vectors derived from AAV serotypes having tropism for and high transduction efficiencies in ocular cells.
  • the method according to the invention wherein the AAV vector is an AAV1, AAV2, AAV3, AAV4, AAV 5, AAV 6, AAV7, AAV 8 or AAV9.
  • the method according to the invention wherein the AAV vector is an AAV1, AAV 2, AAV 5, AAV 7, 8 or AAV 9.
  • a “therapeutically effective amount” of AAV vector as above described is meant a sufficient amount of the AAV vector for the treatment of ocular disease related to mtDNA maintenance. It will be understood, however, that the total dosage of the AAV vector of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts.
  • the compound it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
  • 10 8 to 10 10 viral genomes (vg) are administered per dose in mice.
  • the doses of AAV vectors to be administered in humans may range from 10 10 to 10 12 vg.
  • Administering the recombinant AAV vector of the present invention to the subject is preferably performed by intravenous, intravitreal, subcutaneous delivery.
  • the recombinant AAV vector of the present invention is administered to the subject by the intravitreous injection.
  • the method according to the invention wherein the vector is delivered by intravitreous, subcutaneous or intravenous delivery.
  • the method according to the invention wherein the vector is delivered in retinal ganglion cells, photoreceptors or pigmented epithelium.
  • the invention in a third aspect, relates to a kit for performing the methods of the present invention, wherein said kit comprises means for measuring the expression level of SSBP1 protein and/or detecting SSBP1 SNP that is indicative of subject at risk of having or developing ocular disease related to mtDNA maintenance.
  • the kit may include antibodies, primers, probes, macroarrays or microarrays as above described.
  • the kit may comprise a set of antibodies, primers, or probes as above defined, and optionally pre-labelled.
  • antibodies, primers, or probes may be unlabelled and the ingredients for labelling may be included in the kit in separate containers.
  • the kit may further comprise hybridization reagents or other suitably packaged reagents and materials needed for the particular hybridization protocol, including solid-phase matrices, if applicable, and standards.
  • the kit may further comprise amplification reagents and also other suitably packaged reagents and materials needed for the particular amplification protocol.
  • FIGURES are a diagrammatic representation of FIGURES.
  • Figure 1 SSBP1 protein expression in human retina and fibroblasts.
  • Figure 2 Structural effects of SSBP1 mutations. Densitometric quantification of SSBP1 monomer (left) and dimer (right) in control (Cl) and patient fibroblasts (PI, P2, P3). Data represent mean ⁇ SEM. **P ⁇ 0.01 and ***P ⁇ 0.001, using unpaired t-test. All data are representative of 3 independent experiments.
  • Figure 3 Functional effect of SSBP1 mutation on mtDNA replication.
  • A Quantification of mtDNA. mtDNA content was measured by qPCR and normalised to a nuclear gene (b-hemoglobin) in control (C) and patient fibroblasts (PI, P2, P3).
  • B Quantification of area and volume of mtDNA nucleoids in controls (C) and patient fibroblasts (PI, P2, P3).
  • C Quantification of mtDNA replication rate. Data represent mean ⁇ SEM. *P ⁇ 0.05, **P ⁇ 0.01 using unpaired ttest. Mutation rates in mtDNA from control (C) and patient (P) blood. All data are representative of 3 independent experiments.
  • FIG. 4 Zebrafish Knockdown of SSBP1 causes abnormalities in zebrafish development.
  • A Gross developmental characteristics of zebrafish embryos injected with MOl morpholino (MO SSBPl-1), or non injected at 72 hpf.
  • B Percentage of morpholino- injected embryos with normal phenotype or abnormal developmental characteristics at 72 hpf.
  • NI non injected
  • Std standard control oligo
  • MOl MO SSBPl-1
  • M02 MO SSBP1-2
  • M03 MO SSBP1-3.
  • Genomic DNA is captured using Agilent enrichment solution method with their biotinylated oligonucleotide bank probes (Human All Exon V5, Agilent). The paired-end high- throughput sequencing of 75bp Illumina HiSeq 2000. For a detailed explanation of the protocol, see the publication in Nature Methods(31). Sequence capture, enrichment and elution are performed according to the supplier's protocol and recommendations (SureSelect, Agilent) without modification. Briefly, 3 pg of each genomic DNA is fragmented by sonication and purified to obtain fragments of 150-200 bp.
  • the oligonucleotide adapters for sequencing both ends of the fragments are ligated and repaired with adenine, added to the ends and then purified and enriched by 4-6 PCR cycles. 500 ng of purified libraries are then hybridized to SureSelect capture oligonucleotides bank for 24 hours. After hybridization, washing and elution, the eluted fraction is amplified by 10 to 12 PCR cycles, purified and quantified by quantitative PCR to obtain sufficient DNA template for subsequent downstream processes. Each DNA sample was eluted and enriched then sequenced on an Illumina HiSeq 2000 for 75 b sequences from each end. Image analysis and determination of the bases are made by Illumina RTA software version 1.14 with default settings.
  • Bioinformatics analysis of sequenced data is based on Illumina CASAVA1.8 pipeline.
  • CAS AVAL 8 is a suite of scripts including the sequence alignment to the complete genome (build37 for human), counting and detection of allelic variants (SNPs and indels).
  • the alignment algorithm used is ELANDv2e (Maloney alignment and multi-seed reducing artifactual mismatches). Note that only the positions included in the coordinates of the target regions are preserved.
  • Annotation of genetic variation is carried out internally, including gene annotation (RefSeq and Ensembl), referenced polymorphisms (dbsnpl32, lOOOGenomes) followed by a characterization of the mutation (exon, intron, silent, false nonsense, etc).
  • exomic frequencies are also determined (Homo and HTZ) taking into account at least 150 Exomes sequenced in IntegraGen. The results are made per sample, as tabulated text files. We also provide the control quality results of sequencing targets (depth/coverage).
  • Fibroblasts were cultured from skin biopsies taken after obtaining informed consent from two controls and three affected patients carrying mutations in SSBP1 gene (p.R38Q). Fibroblasts were cultured in two-thirds of RPMI 1640 Medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin-amphotericin B (Thermo Fisher Scientific) and one third of AmnioMax-ClOO basal media (Thermo Fisher Scientific) with Amniomax Cl 00 supplement (Thermo Fisher Scientific).
  • RT-qPCR was used to analyse the expression of SSBP1 mRNA in fibroblasts.
  • Controls and patients fibroblasts were seeded at 7000 cells/well in 100 m ⁇ of medium (RPMEAmniomax) in Seahorse XF96 Cell Culture Microplates coated with 1/100 dilution Corning Matrigel hESC-qualified matrix (Dominique Dutscher) and using 8 replicates. Cells were incubated for 48 hours at 37°C in 5% C02 atmosphere.
  • OCR Cellular oxygen consumption
  • the cells were incubated for 1 h at room temperature with the fluorescent secondary goat anti-mouse IgG-Alexa-Fluor 488 antibody (Molecular Probes) and donkey anti-rabbit IgG-Alexa-Fluor 594 antibody (Molecular Probes), diluted 1/1000 in PBSF. Cells were rinsed three times with PBS for 10 min, and coverslips were mounted using fluorescence Mounting Medium (Dako).
  • the images were acquired using an LSM 700 LIVE DUO Confocal microscope (Carl Zeiss Microscopy). For all imaging, Z-stack images (1024x 1024 pixels) were acquired and processed with the Bitplane Imaris 4 software. Two pictures with at least eight cells per pictures were analyzed for each line. To measure colocalization in the whole cell, images were processed using Imaris 4.0 (Bitplane) software using the automatic thresholding feature for colocalization. Nucleoid fluorescence area and volume were obtained after maximal projection of the images using MetaMorph 5.0 software (Molecular Devices).
  • Protein production was as previously reported (32).
  • the protein sample was cleaned from glycerol by gel filtration, the eluted fractions incubated with a 35nt poly-cytosine single strand DNA (ssDNA) purification (4:2.2 ProtDNA ratio), and dialysed in two steps to 50 mM NaCl, 20 mM TrisHCl pH 7. The final mix was concentrated to 8.6 mg/ml and used for extensive crystallization conditions screening. Crystallization conditions optimization by vapour diffusion method at 20 °C in 24-well plates sitting drop format (Hampton Research) yielded crystals in 11 % PEG1500, 0.1 M cacodylate pH 6.5, 0.2 M magnesium chloride as reservoir solution.
  • ssDNA poly-cytosine single strand DNA
  • EdU labeling (Invitrogen) to detect and quantify mtDNA synthesis
  • primary patient and control fibroblasts were grown on coverslips in Dulbecco's modified Eagle's medium (DMEM; Lonza BE12-604F) supplemented with 10 % fetal calf serum (FCS) (GE Healthcare), in a humidified 37 °C incubator at 5 % C02. All cell lines were routinely tested for mycoplasma contamination and found to be negative.
  • EdU labeling and detection was done as previously described (36) using 100 mM EdU for a 1 hr labeling period and Alexa Fluor 488 azide for detection.
  • Membrane were saturated with 5% non-fat milk dissolved in 0.1% Tween- TBS for 2h at room temperature then incubated overnight at 4°C with polyclonal sheep anti-SSBPl (l pg/ml AF6588 Bio-techne), monoclonal mouse anti-Griml9 (1 : 1000 abl 10240 Abeam), anti-SDHA (1 : 1000 abl4715 Abeam), anti- UQCRCII (1 : 1000 abl4745 Abeam), anti-MTCOl (1 : 1000 abl4705 Abeam), anti-GAPDH (1 :2000 G8795 Sigma) and polyclonal rabbit anti-ATP synthase (1 : 1000 abl51229 Abeam).
  • Membranes were washed three times in 0.1% Tween- TBS and incubated with anti sheep IgG horseradish peroxidase conjugated antibody (1 : 1000 Bio-techne), anti-rabbit IgG, or anti-mouse IgG HRP linked antibody (1 : 10 000 Sigma) for 2h at room temperature.
  • LR Long-Range PCR
  • control and patient DNA samples 50ng/pl were prepared.
  • Mitochondrial DNA was amplified using three pairs of primers: LR1 : FE8285-8314 and Rl : 15600-15574 (wild-type mtDNA fragment of 7315 bp), LR2: F2: 3485-3519 and R2: 14820- 14786 (wild-type mtDNA fragment of 11335 bp) and LR3: F3: 5459-5493 and R3 : 735-701 (wild-type mtDNA fragment of 11845 bp).
  • the PCR conditions are: 1 cycle at 94°C for 1 min; 30 cycles at 98°C for 10 s and 68°C for 11 min; a final extension cycle at 72°C for 10 min.
  • the PCR was performed using TaKara LA Taq DNA polymerase for the first pair of primers, and TaKara Ex Taq DNA polymerase for the other two sets of primers (TaKara Shuzo Corp.).
  • the entire mtDNA molecule was amplified as two over-lapping 8.5 kilo base (kb) fragments.
  • Library preparation was performed using the Ion Plus Fragment Library Kit (Cat. no. 4471269).
  • Sample emulsion PCR, emulsion breaking, and enrichment were performed using the Ion 540 Kit- chefs (Cat. No. A27759) and sequenced on the Ion S5 Sequencer.
  • Sequencing data base calling and mapping were performed using Ion Torrent Suite. Variant analysis was done with a dedicated in-house bioinformatic pipeline including the calling, annotation and prioritization steps.
  • the calling module integrates the prediction of six callers. All of the variant calling formats (VCFs) generated were normalized and decomposed before launching the annotation-prioritization module, which combines the ANNOVAR for variant prioritization.
  • ANNOVAR allowed the inclusion of several databases, i.e. Mitomap and Mitlmpact2, and prioritization tools, i.e. Polyphen2, SIFT and MutationTaster. Searching for mtDNA deletions and insertions was performed using the eKLIPSE program which is based on a soft-clipping analysis (37).
  • MOs antisens morpholino-oligonucleotides
  • Gene Tools LLC MO SSBPl-1 5'-GGTGCTATAATGTTTACCGATATGT-3' (SEQ ID NO: 8), MO SSBP1-2 5'-CTCAACATCTTCTCTGCTGCGTC-3' (SEQ ID NO: 9) MO SSBP1-3 5'- TGAGAAGGCTGCAATAACCCCACGC-3' (SEQ ID NO: 10).
  • Zebrafish embryos from WT-AB
  • Ssbpl MOs and standard controls oligo were injected at 0, lmM each.
  • the predominant clinical symptom exhibited by the present cohort of patients with SSBP1 mutations is an optic neuropathy.
  • DNA samples from 36 patients from four generations in family A (Table 1), showed that 28 patients carried the c. l 13G>A (p.Arg38Glu) mutation in exon 4 of the SSBP1 gene.
  • Three patients sharing the mutation c 133G>A (p.Arg38Glu) were asymptomatic with 20/20 visual acuity, but with some color vision anomalies. All the 18 symptomatic patients had an optic neuropathy with a bilateral pallor of the temporal neuroretinal rim (data not shown). Visual acuity varied from 20/400 to 20/20. Protan or deutan color defects were noted.
  • SSBP1 was preferentially expressed in retinal ganglion cells, photoreceptors and pigmented epithelium (data not shown).
  • Arg38 and Argl07 contact each other at the end of neighboring b-strands of the barrel in a monomer (data not shown).
  • Arg38 is close to the surface that in the homologues contacts the DNA (label (DNA), whereas Argl07 is packed against a hydrophobic pocket at the dimer interface. Therefore, both arginines participate in AB (and BA) dimer interactions.
  • SSBP1 mutation affects mtDNA replication.
  • SSBP1 a new gene associated to mitochondrial DNA depletion diseases and with an unexpected dominant phenotype: a non-syndromic optic atrophy with foveopathy.
  • Whole Exome sequencing on DNA from 8 affected members from a large family with clinical features of ADOA and following target sequencing of the candidate gene in additional ADOA families we have shown the linkage between mutations in SSBP1 and familial ADOA in 5 independent families, expanding the number of genes associated with ADOA.
  • the patients have an optic neuropathy with a clinical presentation similar to OPA1 mutations but also a specific clinical feature, which consists in a singular foveopathy never described in any mitochondriopathy or optic neuropathy.
  • OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci U S A 101 : 15927- 15932.
  • OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res 21 : 12- 20
  • OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis.
  • OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and YmelL. J Cell Biol 178:749-755.
  • Replication factors transiently associate with mtDNA at the mitochondrial inner membrane to facilitate replication.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Les inventeurs rapportent des mutations hétérozygotes dans la protéine SSBP1 de liaison à l'ADN monocaténaire mitochondrial dans de multiples familles non apparentées avec une atrophie optique dominante non syndromique, associée dans la moitié des cas à une frappante occurrence d'une fovéopathie. Le SSBP1 est une protéine clé pour la machinerie de réplication d'ADNmt. Les inventeurs ont identifié deux mutations dans SSBP1 dans des familles avec une atrophie optique dominante et montré que la mutation SSBP1 affecte la réplication de l'ADNmt. Les fibroblastes du patient affichent une formation instable de dimère/tétramère SSBP1 affectant la réplication de l'ADNmt conduisant à une diminution du nombre de copies de l'ADNmt. Ils fournissent des preuves que la déficience de SSBP1 chez l'humain entraîne un nouveau syndrome lié à l'ADNmt conduisant à un défaut visuel isolé. La présente invention concerne un procédé permettant de prédire le risque d'avoir ou de développer une maladie oculaire liée à la maintenance de l'ADNmt par la mesure d'au moins une mutation dans SSBP1. L'invention concerne également le traitement d'une maladie oculaire liée à la maintenance de l'ADN mtBP1 par l'administration d'un inhibiteur de l'expression du gène SSBP1 ou d'un vecteur qui comprend une molécule d'acide nucléique codant pour SSBP1.
PCT/EP2020/066364 2019-06-14 2020-06-12 Procédés et compositions pour le traitement de maladies oculaires associées à la maintenance d'adn mitochondrial WO2020249769A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305764.3 2019-06-14
EP19305764 2019-06-14

Publications (1)

Publication Number Publication Date
WO2020249769A1 true WO2020249769A1 (fr) 2020-12-17

Family

ID=67145746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/066364 WO2020249769A1 (fr) 2019-06-14 2020-06-12 Procédés et compositions pour le traitement de maladies oculaires associées à la maintenance d'adn mitochondrial

Country Status (1)

Country Link
WO (1) WO2020249769A1 (fr)

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126450A2 (fr) 1983-05-19 1984-11-28 Ioannis Dr. Tripatzis Particule et méthode de détection d'antigènes et/ou anticorps utilisant cette particule
US4499052A (en) 1982-08-30 1985-02-12 Becton, Dickinson And Company Apparatus for distinguishing multiple subpopulations of cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4717655A (en) 1982-08-30 1988-01-05 Becton, Dickinson And Company Method and apparatus for distinguishing multiple subpopulations of cells
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
WO1999032619A1 (fr) 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
WO2001036646A1 (fr) 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6573099B2 (en) 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
US20140068797A1 (en) 2012-05-25 2014-03-06 University Of Vienna Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499052A (en) 1982-08-30 1985-02-12 Becton, Dickinson And Company Apparatus for distinguishing multiple subpopulations of cells
US4717655A (en) 1982-08-30 1988-01-05 Becton, Dickinson And Company Method and apparatus for distinguishing multiple subpopulations of cells
EP0126450A2 (fr) 1983-05-19 1984-11-28 Ioannis Dr. Tripatzis Particule et méthode de détection d'antigènes et/ou anticorps utilisant cette particule
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (fr) 1985-03-28 1990-11-27 Cetus Corp
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
WO1999032619A1 (fr) 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6573099B2 (en) 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
WO2001036646A1 (fr) 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US20140068797A1 (en) 2012-05-25 2014-03-06 University Of Vienna Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products

Non-Patent Citations (50)

* Cited by examiner, † Cited by third party
Title
ALEXANDER, C.VOTRUBA, M.PESCH, U.E.THISELTON, D.L.MAYER, S.MOORE, A.RODRIGUEZ, M.KELLNER, U.LEO-KOTTLER, B.AUBURGER, G. ET AL.: "OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28", NAT GENET, vol. 26, 2000, pages 211 - 215
AMATI-BONNEAU, P.VALENTINO, M.L.REYNIER, P.GALLARDO, M.E.BORNSTEIN, B.BOISSIERE, A.CAMPOS, Y.RIVERA, H.DE LA ALEJA, J.G.CARROCCIA,: "OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes", BRAIN, vol. 131, 2008, pages 338 - 351
AOKI ET AL., GENE THERAPY, vol. 18, 2011, pages 936 - 941
ASHTON, N.W.BOLDERSON, E.CUBEDDU, L.O'BYRNE, K.J.RICHARD, D.J.: "Human single-stranded DNA binding proteins are essential for maintaining genomic stability", BMC MOL BIOL, vol. 14, 2013, pages 9, XP021146446, DOI: 10.1186/1471-2199-14-9
BRODERICK, S.REHMET, K.CONCANNON, C.NASHEUER, H.P.: "Eukaryotic single-stranded DNA binding proteins: central factors in genome stability", SUBCELL BIOCHEM, vol. 50, 2010, pages 143 - 163
BURNEY ET AL., CURR. HIV RES., vol. 4, 2006, pages 475 - 484
CAMILLE PIRO-MÉGY ET AL: "Dominant mutations in mtDNA maintenance gene SSBP1 cause optic atrophy and foveopathy", JOURNAL OF CLINICAL INVESTIGATION, 24 September 2019 (2019-09-24), XP055640372, DOI: 10.1172/JCI128513 *
CIPOLAT, S.MARTINS DE BRITO, O.DAL ZILIO, B.SCORRANO, L.: "OPA1 requires mitofusin 1 to promote mitochondrial fusion", PROC NATL ACAD SCI U S A, vol. 101, 2004, pages 15927 - 15932, XP009088997, DOI: 10.1073/pnas.0407043101
COPELAND, W.C.: "Defects of mitochondrial DNA replication", J CHILD NEUROL, vol. 29, 2014, pages 1216 - 1224
CURTH, U.URBANKE, C.GREIPEL, J.GERBERDING, H.TIRANTI, V.ZEVIANI, M.: "Single-stranded-DNA-binding proteins from human mitochondria and Escherichia coli have analogous physicochemical properties", EUR J BIOCHEM, vol. 221, 1994, pages 435 - 443
DELETTRE C ET AL: "NUCLEAR GENE OPA1, ENCODING A MITOCHONDRIAL DYNAMIN-RELATED PROTEINIS MUTATED IN DOMINANT OPTIC ATROPHY", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US, vol. 26, no. 2, 1 October 2000 (2000-10-01), pages 207 - 210, XP000993218, ISSN: 1061-4036, DOI: 10.1038/79936 *
DELETTRE, C.LENAERS, G.GRIFFOIN, J.M.GIGAREL, N.LORENZO, C.BELENGUER, P.PELLOQUIN, L.GROSGEORGE, J.TURC-CAREL, C.PERRET, E. ET AL.: "Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy", NAT GENET, vol. 26, 2000, pages 207 - 210, XP002238680, DOI: 10.1038/79936
DOWDYWEARDEN: "Statistics for Research", 1983, JOHN WILEY & SONS
ELACHOURI, G.VIDONI, S.ZANNA, C.PATTYN, A.BOUKHADDAOUI, H.GAGET, K.YU-WAI-MAN, P.GASPARRE, G.SARZI, E.DELETTRE, C. ET AL.: "OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution", GENOME RES, vol. 21, 2011, pages 12 - 20
FARR, C.L.MATSUSHIMA, Y.LAGINA, A.T., 3RDLUO, N.KAGUNI, L.S.: "Physiological and biochemical defects in functional interactions of mitochondrial DNA polymerase and DNA-binding mutants of single-stranded DNA-binding protein", J BIOL CHEM, vol. 279, 2004, pages 17047 - 17053
FULTON ET AL., CLINICAL CHEMISTRY, vol. 43, no. 9, 1997, pages 1749 - 1756
FULWYLERMCHUGH, METHODS IN CELL BIOLOGY, vol. 33, 1990, pages 613 - 629
GENUARIO, R.WONG, T.W.: "Stimulation of DNA polymerase gamma by a mitochondrial single-strand DNA binding protein", CELL MOL BIOL RES, vol. 39, 1993, pages 625 - 634
GNIRKE, A.MELNIKOV, A.MAGUIRE, J.ROGOV, P.LEPROUST, E.M.BROCKMAN, W.FENNELL, T.GIANNOUKOS, G.FISHER, S.RUSS, C. ET AL.: "Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing", NAT BIOTECHNOL, vol. 27, 2009, pages 182 - 189, XP002658414, DOI: 10.1038/nbt.1523
GOFFART, S.COOPER, H.M.TYYNISMAA, H.WANROOIJ, S.SUOMALAINEN, A.SPELBRINK, J.N.: "Twinkle mutations associated with autosomal dominant progressive external ophthalmoplegia lead to impaired helicase function and in vivo mtDNA replication stalling", HUM MOL GENET, vol. 18, 2009, pages 328 - 340
GOUDENEGE, D.BRIS, C.HOFFMANN, V.DESQUIRET-DUMAS, V.JARDEL, C.RUCHETON, B.BANNWARTH, S.PAQUIS-FLUCKLINGER, V.LEBRE, A.S.COLIN, E. : "eKLIPse: a sensitive tool for the detection and quantification of mitochondrial DNA deletions from next-generation sequencing data", GENET MED, 2018
HENSEN, F.POTTER, A.VAN ESVELD, S.L.TARRES-SOLE, A.CHAKRABORTY, A.SOLA, M.SPELBRINK, J.N.: "Mitochondrial RNA granules are critically dependent on mtDNA replication factors Twinkle and mtSSB", NUCLEIC ACIDS RES., 2019
HUDSON, G.AMATI-BONNEAU, P.BLAKELY, E.L.STEWART, J.D.HE, L.SCHAEFER, A.M.GRIFFITHS, P.G.AHLQVIST, K.SUOMALAINEN, A.REYNIER, P. ET : "Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance", BRAIN, vol. 131, 2008, pages 329 - 337
KABSCH, W., XDS. ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 66, 2010, pages 125 - 132
KACZMARCZYK ET AL., PROC NATL ACAD SCI U S A., vol. 108, 2011, pages 16998 - 17003
KULLAR, P.J.GOMEZ-DURAN, A.GAMMAGE, P.A.GARONE, C.MINCZUK, M.GOLDER, Z.WILSON, J.MONTOYA, J.HAKLI, S.KARPPA, M. ET AL.: "Heterozygous SSBP1 start loss mutation co-segregates with hearing loss and the m.1555A>G mtDNA variant in a large multigenerational family", BRAIN, vol. 141, 2018, pages 55 - 62
LONGLEY, M.J.CLARK, S.YU WAI MAN, C.HUDSON, G.DURHAM, S.E.TAYLOR, R.W.NIGHTINGALE, S.TURNBULL, D.M.COPELAND, W.C.CHINNERY, P.F.: "Mutant POLG2 disrupts DNA polymerase gamma subunits and causes progressive external ophthalmoplegia", AM J HUM GENET, vol. 78, 2006, pages 1026 - 1034
MCFARLAND, R.TAYLOR, R.W.TURNBULL, D.M.: "A neurological perspective on mitochondrial disease", LANCET NEUROL, vol. 9, 2010, pages 829 - 840, XP027598997, DOI: 10.1016/S1474-4422(10)70116-2
MILONE, M.WANG, J.LIEWLUCK, T.CHEN, L.C.LEAVITT, J.A.WONG, L.J.: "Novel POLG splice site mutation and optic atrophy", ARCH NEUROL, vol. 68, 2011, pages 806 - 811
MIRALLES FUSTE, J.SHI, Y.WANROOIJ, S.ZHU, X.JEMT, E.PERSSON, O.SABOURI, N.GUSTAFSSON, C.M.FALKENBERG, M.: "In vivo occupancy of mitochondrial single- stranded DNA binding protein supports the strand displacement mode of DNA replication", PLOS GENET, vol. 10, 2014, pages el004832
MURATORI, METHODS MOL. BIOL., vol. 614, 2010, pages 111 - 24
NERINGA JURKUTE ET AL: "SSBP1 mutations in dominant optic atrophy with variable retinal degeneration", ANNALS OF NEUROLOGY., vol. 86, no. 3, 12 July 2019 (2019-07-12), BOSTON, US, pages 368 - 383, XP055640377, ISSN: 0364-5134, DOI: 10.1002/ana.25550 *
OLICHON, A.ELACHOURI, G.BARICAULT, L.DELETTRE, C.BELENGUER, P.LENAERS, G.: "OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis", CELL DEATH DIFFER, vol. 14, 2007, pages 682 - 692, XP009088983, DOI: 10.1038/sj.cdd.4402048
RAJALA, N.GERHOLD, J.M.MARTINSSON, P.KLYMOV, A.SPELBRINK, J.N: "Replication factors transiently associate with mtDNA at the mitochondrial inner membrane to facilitate replication", NUCLEIC ACIDS RES, vol. 42, 2014, pages 952 - 967
SONG, Z.CHEN, H.FIKET, M.ALEXANDER, C.CHAN, D.C.: "OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and YmelL", J CELL BIOL, vol. 178, 2007, pages 749 - 755, XP009089036
SPELBRINK, J.N.LI, F.Y.TIRANTI, V.NIKALI, K.YUAN, Q.P.TARIQ, M.WANROOIJ, S.GARRIDO, N.COMI, G.MORANDI, L. ET AL.: "Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria", NAT GENET, vol. 28, 2001, pages 223 - 231
STEWART, J.D.SCHOELER, S.SITARZ, K.S.HORVATH, R.HALLMANN, K.PYLE, A.YU-WAI-MAN, P.TAYLOR, R.W.SAMUELS, D.C.KUNZ, W.S. ET AL.: "POLG mutations cause decreased mitochondrial DNA repopulation rates following induced depletion in human fibroblasts", BIOCHIM BIOPHYS ACTA, vol. 1812, 2011, pages 321 - 325, XP028150823, DOI: 10.1016/j.bbadis.2010.11.012
VALENTINA DEL DOTTO ET AL: "SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder", JOURNAL OF CLINICAL INVESTIGATION, 24 September 2019 (2019-09-24), XP055640371, DOI: 10.1172/JCI128514 *
VAN DYCK, E.FOURY, F.STILLMAN, B.BRILL, S.J.: "A single-stranded DNA binding protein required for mitochondrial DNA replication in S. cerevisiae is homologous to E. coli SSB", EMBO J, vol. 11, 1992, pages 3421 - 3430
VAN GOETHEM, G.DERMAUT, B.LOFGREN, A.MARTIN, J.J.VAN BROECKHOVEN, C.: "Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions", NAT GENET, vol. 28, 2001, pages 211 - 212
VENCLOVAS, C.GINALSKI, K.KANG, C.: "Sequence-structure mapping errors in the PDB: OB-fold domains", PROTEIN SCI, vol. 13, 2004, pages 1594 - 1602
WANG, Y.HU, L.ZHANG, X.ZHAO, H.XU, H.WEI, Y.JIANG, H.XIE, C.ZHOU, Y.ZHOU, F.: "Downregulation of Mitochondrial Single Stranded DNA Binding Protein (SSBP1) Induces Mitochondrial Dysfunction and Increases the Radio sensitivity in Non-Small Cell Lung Cancer Cells", J CANCER, vol. 8, 2017, pages 1400 - 1409
WANROOIJ, S.FALKENBERG, M.: "The human mitochondrial replication fork in health and disease", BIOCHIM BIOPHYS ACTA, vol. 1797, 2010, pages 1378 - 1388, XP027089724
WANROOIJ, S.GOFFART, S.POHJOISMAKI, J.L.YASUKAWA, T.SPELBRINK, J.N.: "Expression of catalytic mutants of the mtDNA helicase Twinkle and polymerase POLG causes distinct replication stalling phenotypes", NUCLEIC ACIDS RES, vol. 35, 2007, pages 3238 - 3251
WEBB, B.SALI, A.: "Protein Structure Modeling with MODELLER", METHODS MOL BIOL, vol. 1654, 2017, pages 39 - 54
WINN, M.D.BALLARD, C.C.COWTAN, K.D.DODSON, E.J.EMSLEY, P.EVANS, P.R.KEEGAN, R.M.KRISSINEL, E.B.LESLIE, A.G.MCCOY, A. ET AL.: "Overview of the CCP4 suite and current developments", ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 67, 2011, pages 235 - 242
YANG, C.CURTH, U.URBANKE, C.KANG, C.: "Crystal structure of human mitochondrial single-stranded DNA binding protein at 2.4 A resolution", NAT STRUCT BIOL, vol. 4, 1997, pages 153 - 157
YOU WANG ET AL: "Downregulation of Mitochondrial Single Stranded DNA Binding Protein (SSBP1) Induces Mitochondrial Dysfunction and Increases the Radiosensitivity in Non-Small Cell Lung Cancer Cells", JOURNAL OF CANCER, vol. 8, no. 8, 12 May 2017 (2017-05-12), AU, pages 1400 - 1409, XP055640362, ISSN: 1837-9664, DOI: 10.7150/jca.18170 *
YOUNG, M.J.COPELAND, W.C.: "Human mitochondrial DNA replication machinery and disease", CURR OPIN GENET DEV, vol. 38, 2016, pages 52 - 62, XP029767524, DOI: 10.1016/j.gde.2016.03.005
ZETSCHE ET AL.: "Cpfl is a Single RNA-guided Endonuclease of a Class 2 CRISPR-Cas System", CELL, vol. 163, 2015, pages 1 - 13

Similar Documents

Publication Publication Date Title
Sang et al. CircSNCA downregulation by pramipexole treatment mediates cell apoptosis and autophagy in Parkinson’s disease by targeting miR-7
Bilsen et al. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts
CN107115352B (zh) 微rna和包含微rna的组合物
JP2021523369A (ja) 黄斑変性症を評価するための方法
KR20190095074A (ko) 뇌 종양 동물 모델 및 이의 제조 방법
Lu et al. Polymorphic variation in cytochrome oxidase subunit genes
Sun et al. A novel mutation of PANK4 causes autosomal dominant congenital posterior cataract
CN113966396A (zh) 遗传性神经病和相关障碍的治疗和检测
Verreault et al. Identification of growth hormone receptor as a relevant target for precision medicine in low‐EGFR expressing glioblastoma
Sabater-Arcis et al. Msi2 enhances muscle dysfunction in a myotonic dystrophy type 1 mouse model
WO2020249769A1 (fr) Procédés et compositions pour le traitement de maladies oculaires associées à la maintenance d'adn mitochondrial
US11273161B2 (en) Methods of treating autism spectrum disorders
US20220251569A1 (en) Treatment and prevention of disease mediated by wwp2
EP4232605A2 (fr) Méthodes et compositions pour diagnostiquer et traiter un cancer de la prostate sur la base d'un arn long non codant chevauchant le gène lck régulant la croissance des cellules du cancer de la prostate
EP4110465A1 (fr) Biomarqueurs et cibles moléculaires pour dystrophie cornéenne endothéliale de fuchs et glaucome
Zhang et al. Patterns of gene expression and allele-specific expression vary among macular tissues and clinical stages of Age-related Macular Degeneration
CN113151432A (zh) 神经退行性疾病检测和治疗的新靶标
CN114032296B (zh) Psmd14在系膜增生性肾小球肾炎中的应用
US11946928B2 (en) Methods and compositions relating to airway dysfunction
CN108752452B (zh) Sars及其突变体的应用
US20240299347A1 (en) Methods and compositions to treat huntington's disease by targeting alox5- mediated ferroptosis
US20230028590A1 (en) Als treatment method, als pharmaceutical composition, and als diagnostic method
US20230232794A1 (en) Animal model of brain tumor and manufacturing method of animal model
WO2023005959A1 (fr) Compositions et méthodes de traitement de la maladie d'alzheimer
WO2023175099A1 (fr) Agents pour le traitement de troubles liés au complément

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20732219

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20732219

Country of ref document: EP

Kind code of ref document: A1